Profund Advisors LLC Buys 12,904 Shares of PTC Therapeutics, Inc. $PTCT

Profund Advisors LLC increased its position in PTC Therapeutics, Inc. (NASDAQ:PTCT) by 56.2% during the 3rd quarter, Holdings Channel reports. The institutional investor owned 35,877 shares of the biopharmaceutical company’s stock after purchasing an additional 12,904 shares during the period. Profund Advisors LLC’s holdings in PTC Therapeutics were worth $2,324,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. BlackRock Inc. purchased a new position in shares of PTC Therapeutics during the second quarter valued at approximately $1,139,089,000. Jupiter Topco LLC bought a new stake in PTC Therapeutics in the second quarter valued at $590,182,000. Janus Henderson Group PLC boosted its holdings in PTC Therapeutics by 48.3% in the first quarter. Janus Henderson Group PLC now owns 7,193,433 shares of the biopharmaceutical company’s stock valued at $489,997,000 after acquiring an additional 2,342,101 shares in the last quarter. William Blair Investment Management LLC purchased a new position in PTC Therapeutics during the 2nd quarter valued at $140,520,000. Finally, Bank of America Corp DE purchased a new position in PTC Therapeutics during the 2nd quarter valued at $118,462,000.

Insider Transactions at PTC Therapeutics

In related news, Director Glenn Steele, Jr. sold 12,000 shares of PTC Therapeutics stock in a transaction that occurred on Wednesday, September 30th. The shares were sold at an average price of $65.16, for a total transaction of $781,920.00. Following the transaction, the director directly owned 22,500 shares of the company’s stock, valued at $1,466,100. This trade represents a 34.78% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Michael Schmertzler sold 2,500 shares of the business’s stock in a transaction on Wednesday, October 14th. The stock was sold at an average price of $59.61, for a total value of $149,025.00. Following the completion of the transaction, the director directly owned 1,291,594 shares of the company’s stock, valued at approximately $76,991,918.34. The trade was a 0.19% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 77,370 shares of company stock valued at $5,322,261. Company insiders own 5.30% of the company’s stock.

Key Stories Impacting PTC Therapeutics

Here are the key news stories impacting PTC Therapeutics this week:

• Positive Sentiment: Raised 2026 outlook and strong revenue growth: PTC reported third-quarter revenue of approximately $358 million, up 69.6% year over year, including $276 million in product revenue. Management increased full-year 2026 revenue guidance to $1.29 billion-$1.32 billion and product revenue guidance to $960 million-$990 million. Sephience revenue reached $182 million, supported by U.S. growth and international expansion. PTC Therapeutics Provides Corporate Update and Reports Third Quarter 2026 Financial Results
• Positive Sentiment: Analysts raised price targets: TD Cowen lifted its target from $90 to $95 and maintained a “buy” rating. Wells Fargo raised its target from $109 to $112 and kept an “overweight” rating, signaling substantial potential upside based on the current valuation. TD Cowen recommendations Wells Fargo price target update
• Positive Sentiment: Pipeline expansion: PTC acquired ST-920, a Fabry disease gene therapy, and expects to complete its biologics license application submission in the fourth quarter, adding a potential future growth catalyst. PTC corporate update
• Neutral Sentiment: Royal Bank of Canada raised its price target from $75 to $77 but retained a “sector perform” rating, indicating improved valuation expectations without a bullish change in its recommendation. RBC recommendations
• Negative Sentiment: Quarterly loss weighed on sentiment: PTC reported a GAAP loss of $0.62 per share, versus analysts’ expected profit of $0.14. Although revenue exceeded estimates, the earnings miss and swing from a year-earlier profit create near-term concern. Some reports cite adjusted earnings of $0.61 per share, highlighting a difference in reporting methodology. PTC Therapeutics swings to Q3 loss

PTC Therapeutics Stock Performance

Shares of PTCT stock opened at $59.97 on Monday. The stock has a fifty day simple moving average of $65.36 and a two-hundred day simple moving average of $70.78. The firm has a market capitalization of $5.01 billion, a PE ratio of -42.84, a PEG ratio of 1.81 and a beta of 0.52. PTC Therapeutics, Inc. has a 52-week low of $58.80 and a 52-week high of $90.87.

PTC Therapeutics (NASDAQ:PTCT) last announced its earnings results on Thursday, October 29th. The biopharmaceutical company reported ($0.62) EPS for the quarter, missing analysts’ consensus estimates of $0.14 by ($0.76). The firm had revenue of $357.81 million during the quarter, compared to analysts’ expectations of $306.43 million. The business’s revenue for the quarter was up 69.6% on a year-over-year basis. During the same period last year, the business posted $0.20 EPS. On average, sell-side analysts forecast that PTC Therapeutics, Inc. will post 1.19 EPS for the current fiscal year.

Analysts Set New Price Targets

PTCT has been the topic of a number of research reports. Cantor Fitzgerald boosted their target price on shares of PTC Therapeutics from $130.00 to $137.00 and gave the company an “overweight” rating in a report on Tuesday, September 22nd. Zacks Research downgraded PTC Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Thursday, August 6th. Weiss Ratings raised PTC Therapeutics from a “sell (d)” rating to a “sell (d+)” rating in a research report on Thursday, October 8th. Wall Street Zen cut shares of PTC Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday. Finally, Truist Financial began coverage on shares of PTC Therapeutics in a report on Friday, October 16th. They issued a “hold” rating and a $62.00 target price for the company. One analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, three have given a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $95.64.

About PTC Therapeutics

PTC Therapeutics, Inc is a biopharmaceutical company focused on discovering, developing and commercializing medicines for rare diseases. Its research programs include small-molecule treatments, gene therapies and other approaches designed to address conditions with limited or no available treatment options.

The company’s commercial portfolio has included Emflaza (deflazacort), a corticosteroid approved in the United States to treat Duchenne muscular dystrophy, and Upstaza (eladocagene exuparvovec), a gene therapy authorized in the European Union for aromatic L-amino acid decarboxylase deficiency.